Junevity Closes $20 Million Seed Round to Pioneer Cell Reprogramming with siRNA for Type 2 Diabetes and Obesity
Junevity, a pioneering biotechnology company with the ambitious mission of extending human healthspan through advanced cell reprogramming, today announced it has successfully expanded its Seed financing to a total of $20 million with an additional $10 million investment. The new capital was jointly led by Goldcrest Capital and Godfrey Capital, providing the runway necessary to…